Press Releases

Date Title
Toggle Summary Kura Oncology Reports Third Quarter 2016 Financial Results
Management to host webcast and conference call today at 1:30 p.m. PST/4:30 p.m. EST LA JOLLA, Calif. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of
Toggle Summary Kura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology Conference
LA JOLLA, Calif. , Nov. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today presented preclinical findings and data from the company’s ongoing Phase 2 trial in HRAS mutant solid tumors at the 9th European Scientific Oncology Conference
Toggle Summary Kura Oncology to Participate in Two Upcoming Investor Conferences
LA JOLLA, Calif. , Nov. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company at two upcoming investor
Toggle Summary Kura Oncology to Report Third Quarter 2016 Financial Results
Management to host webcast and conference call on November 7, 2016 at 1:30 p.m. PST/4:30 p.m. EST LA JOLLA, Calif. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the
Toggle Summary Kura Oncology to Participate in the 9th European Scientific Oncology Conference
LA JOLLA, Calif. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 9th European Scientific Oncology Conference . Antonio Gualberto , M.D., Ph.D., Chief Medical Officer, will participate and
Toggle Summary Kura Oncology to Participate in the 2016 Aegis Growth Conference
LA JOLLA, Calif. , Sept. 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Aegis Growth Conference . Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an
Toggle Summary Kura Oncology to Participate in the 5th Annual Gateway Conference
LA JOLLA, Calif. , Sept. 02, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Gateway Conference . Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an
Toggle Summary Kura Oncology Reports Second Quarter 2016 Financial Results
Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment Management to host webcast and conference call today at 1:15 p.m. PDT / 4:15 p.m. EDT LA JOLLA, Calif. , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.
Toggle Summary Kura Oncology to Report Second Quarter 2016 Financial Results
Management to host webcast and conference call on August 10, 2016 at 1:15 p.m. PDT/4:15 p.m. EDT LA JOLLA, Calif. , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced it will report second quarter 2016 financial results
Toggle Summary Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
LA JOLLA, Calif. , June 16, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced the first patient has been dosed in a Phase 2 clinical trial of tipifarnib in patients with lower risk myelodysplastic syndromes (MDS).